Clinical trial NCT01816555: Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma
Official title: Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2013-03-22
Enrollment: 1
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is for adult females who have been newly diagnosed with breast cancer that includes surgery as part of standard cancer treatment. This is a research study combining Vitamin D (an over the counter medication) with the standard of care (or the established and approved treatment), surgery. Evidence shows that women who are Vitamin D3 deficient have a higher risk of breast cancer and breast cancer recurrence. The purpose of this study is to find out the effects of Vitamin D3 during the treatment period for Stage I-II breast cancer. Screening tests will be done to determine if subjects are eligible to participate in this study. If subjects are eligible and they agree to participate, they will be assigned to one of two groups which will receive different amounts of vitamin D. Subjects will be asked to keep a medication diary. Subjects may remain on treatment for approximately 56 days.


Eligibility criteria: Inclusion Criteria:

* Patients must be greater than or equal to 18 years of age.
* Patients must have a newly diagnosed invasive ductal breast carcinoma, Stage I-II.
* Patients who have completed their surgical and radiation therapy.
* Patients must have SWOG performance status of 0, 1 or 2.
* Patients must have adequate organ function as defined by:
* Hgb \> 8.0 gm/dl, WBC \> 3,500, platelet count \> 100,000
* Bilirubin \< 2.0 mg/dl, SGOT \< 4x upper limit of normal
* Creatinine \< 2.0 mg/dl or calculated creatinine clearance \> 50 ml/min
* Patients must have a serum calcium - phosphate product that is less than 70.
* Patients must have recovered from any prior surgery.
* Patients must be willing to use appropriate contraception if of child-bearing potential.
* Patients may be on standard of care maintenance dose Vit D3

Exclusion Criteria:

* Patients with histology of lobular carcinoma.
* Patients with metastatic disease.
* Pregnant or lactating women.
* Male gender.
* Patients with a history of sarcoidosis.
* Patients with any history of idiopathic urinary calcium stone disease, chronic hypercalcemia, or gastrointestinal malabsorptive conditions.
* Patients who have received any of the following treatments within the last 14 days prior to study registration will be excluded.
* Lithium
* Digitalis
* Thiazide diuretics
* Calcium supplementation during 1,25-dihydroxyvitamin D3 treatment
* Bisphosphonates
* Teriparatide
* Aluminum Hydroxide
* Bile Acid sequestrants
* Repletion dose VitD3 in setting of known Vit D3 deficiency or insufficiency
* Patients who have received concurrent corticosteroid treatments within the last 14 days prior to study registration will be excluded.
* Known HIV positive.
* Patients with an active infection requiring antibiotic therapy.
* Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization and is deemed by her physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
* Patients undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy.

Primary outcomes:
measure: Compare the differences in the T cell phenotype and function using PBMCs from patients in different cohorts
timeFrame: Prior to Treatment (Baseline), Week 4 and Week 8
Secondary outcomes:
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
References: